[1] SOBREIRA E,PIRES R F,CIZMARIK M,et al.Phenotypic and genotypic heterogeneity in Gaucher disease type1:a comparison between Brazil and the rest-of-the world[J].Mol GenetMetab,2007,90(1):81-86. [2] BRADY R O, KANFER J N, SHAPIRO D.Metabolism of glucocerebrosides Ⅱ.Evidence of an enzymatic deficiency in Gaucher's disease[J].Biochem Biophys Res Commun,1965,18:221-225. [3] 刘林玉,杜司晨,张进, 等.戈谢病致病机制及治疗方法[J].遗传,2015,37(6):510-516. [4] 中华医学会儿科学分会遗传代谢内分泌学组,中华医学会儿科学分会血液学组,中华医学会血液学分会红细胞疾病(贫血)学组.中国戈谢病诊治专家共识(2015)[J].中华儿科杂志,2015,53(4):256-261. [5] 段彦龙,张永红,臧晏, 等.酶替代治疗戈谢病72例[J].中华儿科杂志,2006,44(9):653-656. [6] GRABOWSKI G A.Phenotype,diagnosis,and treatment of Gaucher's disease[J].Lancet, 2008,372(9645):1263-1271. [7] WENSTRUP R J, ROCA-ESPIAU M,WEINREB N J,et al.Skeletal aspects of Gaucher disease:a review[J].Br J Radiol,2002,75(Suppl1):A2-A12. [8] CHAN A,HOLLERAN W M,FERGUSON T,et al.Skin ultrastructural findings in type 2 Gaucher disease:diagnostic implications[J]. Mol Genet Metab,2011,104(4):631-636. [9] ELSTEIN D,ABRAHAMOV A,ALTARESCU G,et al.Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy[J].Blood Cells Mol Dis,2013,50(2):140. [10] KHALIFA A S,TANTAWY A A,SHAWKY R M,et al.Outcome of enzyme replacement therapy in children with Gaucher disease:The Egyptian experience[J].Egypt J Med Human Genet,2011,12(1):9-14. [11] 李平,袁弥满,蔡则骥, 等.大鼠部分脾栓塞后脾脏巨噬细胞吞噬功能的定量测定[J].华中医学杂志,2001,25(6):318-319. [12] LEE J Y,LEE B H,KIM G H,et al.Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups[J].Korean J Pediatr,2012,55(2):48-53. [13] WANG G N,TWIGG G,BUTTERS T D,et al.Synthesis of N-substituted E-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease[J].Org Biomol Chem,2012,10(15):2923-2927. [14] SINGLA M,ARIVARASAN K,DHIR V,et al.Medical image.an unusual cause of massive splenomegaly in an adult.Gaucher's disease[J].N Z Med J,2012,125(1361):98-101. [15] SELDEN N R,UZRI A,HUHN S L,et al.Central nervoussystem stem eell transplantation for children with neuronal ceroid lipofuscinosis[J].J Neurosurg Pediatr,2013,11(6):643-652. [16] ENQUIST I B,NILSSON E,OOKA A,et al.Effective cell and gene therapy in a murine model of Gaucher disease[J].Proc Natl Acad Sci USA,2006,103(37):13819-13824. [17] TISCORNIA G,VIVAS E L,MATALONGA L,et al.Neuronopathic Gaucher's disease:induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds[J].Hum Mol Genet,2013,22(4):633-645. [18] MASSARO G,MATTAR C N Z,WONG A M S, et al.Fetal gene therapy for neurodegenerative disease of infants[J].Nat Med,2018.DOI:10.1038/s41591-018-0106-7. [19] MATTAR C N,ANDREW M S,HOEFER K, et al.Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates[J].FASEB J,2015,29(9):3876-3888. |